

# Whole-exome Sequencing for the Identification of Rare Variants in Primary Immunodeficiency Genes in Children With Sepsis: A Prospective, Population-based Cohort Study

Alessandro Borghesi,<sup>1,2,3,a</sup> Johannes Trück,<sup>4,5,a</sup> Samira Asgari,<sup>1,2,6,7</sup> Vanessa Sancho-Shimizu,<sup>8,9</sup> Philipp K. A. Agyeman,<sup>10</sup> Evangelos Bellos,<sup>8</sup> Eric Giannoni,<sup>11</sup> Martin Stocker,<sup>12</sup> Klara M. Posfay-Barbe,<sup>13</sup> Ulrich Heiningner,<sup>14</sup> Sara Bernhard-Stirnemann,<sup>15</sup> Anita Niederer-Loher,<sup>16</sup> Christian R. Kahlert,<sup>17</sup> Giancarlo Natalucci,<sup>17</sup> Christa Reilly,<sup>4</sup> Thomas Riedel,<sup>18</sup> Claudia E. Kuehni,<sup>19</sup> Christian W. Thorball,<sup>1,2</sup> Nimisha Chaturvedi,<sup>1,2</sup> Federico Martinon-Torres,<sup>20,21</sup> Taco W. Kuijpers,<sup>22</sup> Lachlan Coin,<sup>23</sup> Victoria Wright,<sup>8</sup> Jethro Herberg,<sup>8</sup> Michael Levin,<sup>8</sup> Christoph Aebi,<sup>10</sup> Christoph Berger,<sup>4</sup> Jacques Fellay,<sup>1,2,24</sup> and Luregn J. Schlapbach<sup>4,25,26</sup>; for the European Childhood Life-threatening Infectious Disease Study (EUCLIDS) Consortium and the Swiss Paediatric Sepsis Study

<sup>1</sup>Swiss Institute of Bioinformatics, Lausanne, Switzerland, <sup>2</sup>Global Health Institute, School of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland, <sup>3</sup>Neonatal Intensive Care Unit, Fondazione Institute for Research, Hospitalization and Health Care (IRCCS) Policlinico San Matteo, Pavia, Italy, <sup>4</sup>University Children's Hospital Zurich and the Children's Research Center, Zurich, Switzerland, <sup>5</sup>University of Zurich, Zurich, Switzerland, <sup>6</sup>Division of Genetics and Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA, <sup>7</sup>Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA, <sup>8</sup>Section of Paediatrics, Imperial College London, London, United Kingdom, <sup>9</sup>Section of Virology, Imperial College London, London, United Kingdom, <sup>10</sup>Department of Paediatrics, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland, <sup>11</sup>Service of Neonatology, Department Woman-Mother-Child, and Infectious Diseases Service, Department of Medicine, Lausanne University Hospital, Lausanne, Switzerland, <sup>12</sup>Department of Paediatrics, Children's Hospital Lucerne, Lucerne, Switzerland, <sup>13</sup>Paediatric Infectious Diseases Unit, Children's Hospital of Geneva, University Hospitals of Geneva, Geneva, Switzerland, <sup>14</sup>Infectious Diseases and Vaccinology, University of Basel Children's Hospital, Basel, Switzerland, <sup>15</sup>Children's Hospital Aarau, Aarau, Switzerland, <sup>16</sup>Children's Hospital of Eastern Switzerland St. Gallen, St. Gallen, Switzerland, <sup>17</sup>Department of Neonatology, University Hospital Zurich, Zurich, Switzerland, <sup>18</sup>Department of Paediatrics, Cantonal Hospital Graubünden, Chur, Switzerland, <sup>19</sup>Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland, <sup>20</sup>Translational Paediatrics and Infectious Diseases Section, Paediatrics Department, Santiago de Compostela, Spain, <sup>21</sup>Instituto de Investigación Sanitaria de Santiago, Genetics, Vaccines, Infectious Diseases and Paediatrics Research Group, Santiago de Compostela, Spain, <sup>22</sup>Academic Medical Center, Emma Children's Hospital, University of Amsterdam, Amsterdam, The Netherlands, <sup>23</sup>Institute of Molecular Biosciences, The University of Queensland, Brisbane, Australia, <sup>24</sup>Precision Medicine Unit, Lausanne University Hospital, Lausanne, Switzerland, <sup>25</sup>Paediatric Critical Care Research Group, Child Health Research Centre, The University of Queensland, Brisbane, Australia, and <sup>26</sup>Paediatric Intensive Care Unit, Queensland Children's Hospital, Children's Health Queensland, Brisbane, Australia

**Background.** The role of primary immunodeficiencies (PID) in susceptibility to sepsis remains unknown. It is unclear whether children with sepsis benefit from genetic investigations. We hypothesized that sepsis may represent the first manifestation of underlying PID. We applied whole-exome sequencing (WES) to a national cohort of children with sepsis to identify rare, predicted pathogenic variants in PID genes.

**Methods.** We conducted a multicenter, population-based, prospective study including previously healthy children aged  $\geq 28$  days and  $< 17$  years admitted with blood culture-proven sepsis. Using a stringent variant filtering procedure, analysis of WES data was restricted to rare, predicted pathogenic variants in 240 PID genes for which increased susceptibility to bacterial infection has been reported.

**Results.** There were 176 children presenting with 185 sepsis episodes who underwent WES (median age, 52 months; interquartile range, 15.4–126.4). There were 41 unique predicted pathogenic PID variants (1 homozygous, 5 hemizygous, and 35 heterozygous) found in 35/176 (20%) patients, including 3/176 (2%) patients carrying variants that were previously reported to lead to PID. The variants occurred in PID genes across all 8 PID categories, as defined by the International Union of Immunological Societies. We did not observe a significant correlation between clinical or laboratory characteristics of patients and the presence or absence of PID variants.

**Conclusions.** Applying WES to a population-based cohort of previously healthy children with bacterial sepsis detected variants of uncertain significance in PID genes in 1 out of 5 children. Future studies need to investigate the functional relevance of these variants to determine whether variants in PID genes contribute to pediatric sepsis susceptibility.

**Keywords.** child; exome sequencing; genomics; immunodeficiency; sepsis; variant; variants of uncertain significance.

Received 29 March 2019; editorial decision 23 February 2020; accepted 15 March 2020; published online March 18, 2020.

<sup>a</sup>A.B. and J.T. contributed equally to this work.

Correspondence: L. J. Schlapbach, Paediatric Critical Care Research Group, Child Health Research Centre, The University of Queensland, South Brisbane QLD 4101 Australia (l.schlapbach@uq.edu.au).

Clinical Infectious Diseases® 2020;71(10):e614–23

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact [journals.permissions@oup.com](mailto:journals.permissions@oup.com) DOI: 10.1093/cid/ciaa290

The incidence of sepsis is highest at the extremes of age: in the very young and the very old [1–3]. In high-income countries, 35% to 50% of pediatric sepsis deaths occur in previously healthy infants and children, despite access to vaccinations, health care, and effective antibiotics [2, 4]. Sepsis-related morbidity in the absence of risk factors remains high and is associated with significant sequelae, such as amputations and neurodevelopmental disabilities [5]. The mechanisms underlying susceptibility to severe infectious diseases in otherwise healthy patients remain largely unknown, but epidemiological studies suggest a strong genetic contribution [6]. It has been

proposed that severe infections in childhood are more likely to be the manifestation of rare, single-gene disorders, compared with infections occurring in adults [7, 8]. Case reports anecdotally show that life-threatening infections of childhood may represent the first manifestation of primary immunodeficiency (PID) [8]. However, little is known about the prevalence of PID gene variants in patients with sepsis, and there is a lack of guidance to advise on genetic or immunologic investigations after a first sepsis episode [9, 10].

Whole-exome sequencing (WES) has emerged as a powerful tool to identify disease-causing genetic variants [11, 12]. We recently reported the successful application of WES in a highly selected cohort of pediatric sepsis cases [9]. WES has never been used to assess the genetic contribution to sepsis in larger population-based cohorts.

Although WES is insufficient to determine the functional relevance of genetic variants, it enables their identification in those PID genes previously reported to be associated with bacterial infection. We hypothesized that those rare and predicted pathogenic genetic variations in PID genes that are associated with bacterial infection are more common in previously healthy children who develop blood culture–positive, community-acquired sepsis, compared with genomic reference cohorts.

## METHODS

### Study Design

We conducted a prospective, observational, multicenter cohort study enrolling children presenting with blood culture–proven bacterial sepsis in the 10 major pediatric hospitals in Switzerland between 1 September 2011 and 31 December 2015. The study protocol and details of the Swiss Pediatric Sepsis Study have been reported elsewhere [13, 14]. Written informed consent for genetic analyses was obtained from parents or legal guardians. The ethical review board approved the study (Cantonal Ethics Committee, University of Bern, KEK-029/11).

### Inclusion Criteria

Previously healthy children aged >28 days and <17 years with community-acquired, blood culture–proven bacterial sepsis due to *Streptococcus pneumoniae*, *Staphylococcus aureus*, Group A and B streptococcus, *Neisseria meningitidis*, or *Haemophilus influenzae*, as defined by 2005 pediatric sepsis consensus definitions [15], were eligible. These pathogens were selected because they represent the most common pathogens causing community-acquired sepsis in children without comorbidities.

### Exclusion Criteria

Prematurely born neonates, infants <28 days (or <44 weeks of gestational age), and children with comorbidities, including any chronic inborn or acquired medical conditions, known primary or secondary immunodeficiency, recent trauma, surgery or burns, and children with hospital-acquired infections

(>48 hours after admission) or with pathogens other than those listed under the inclusion criteria were not considered for WES.

### Whole-exome Sequencing, Read Mapping, Variant Calling, and Variant Annotation

Blood samples were collected and processed as reported elsewhere [9]. WES was performed on Illumina HiSeq 2500 at the Lausanne Genomic Technology Facility (Supplementary Methods; Supplementary Tables 1, 2 and 3). Sequencing reads were mapped to the human reference genome hg19 using BWA-MEM v0.7.15 [16, 17]. The Genome Analysis Toolkit v3.8 Sequence Data Processing Tools and Variant Discovery Tools were used according to best practices [18, 19]. These included base quality score recalibration and per-sample, simultaneous calling of single nucleotide variants and small insertions and deletions (indels) with the HaplotypeCaller tool, followed by joint genotyping and quality filtering (only variants with genotype quality >100 and read depth >20 were kept for a downstream analysis). Genetic and functional annotation included putative effect predictions for Sequence Ontology terms, putative loss-of-function predictions, and effect predictions from multiple algorithms. Each variant was annotated with information on minor allele frequency (MAF) in several public databases, including the 1000 Genomes project Phase 1 (n = 1092), the NHLBI exome sequencing project (n = 7520), the Genome Aggregation Database (gnomAD; n = 138632), and 519 in-house control exomes.

### Filtering and Identification of Candidate Genomic Variants in Primary Immunodeficiency Genes

Analyses were restricted to nonsynonymous, exonic variants that are rare in the general population (MAF <0.01 for homozygous/hemizygous and <0.0001 for heterozygous variants in the gnomAD database). We also filtered out variants with a MAF >0.01 in our in-house exome database. We restricted the analysis to variants in 240 PID genes previously reported to be associated with bacterial disease as defined by the International Union of Immunological Societies (IUIS) [20]. We further prioritized variants by filtering for predicted pathogenicity, keeping only variants with a putative deleterious impact according to the Combined Annotation Dependent Depletion v1.3 score [21], resulting in putatively pathogenic variants. For every putatively pathogenic variant, PubMed entries between 1.1.1970 and 30.6.2019 were searched for reports on patients with PID and bacterial infections carrying the exact variant. The study did not include functional validation. Therefore, the filtered rare and predicted pathogenic variants in the selected PID genes were labelled as variants of uncertain significance (VUS).

### Statistical Analysis

Descriptive statistics are presented as median and interquartile ranges for continuous variables and frequencies and percentages for categorical variables. We used the  $\chi^2$  test of proportions

and the Wilcoxon nonparametric rank sum test to compare subgroups. We considered a 2-sided  $P$  value of  $<.05$  as significant. Analyses and graphs were done using R (R Core Team, 2019; R Foundation for Statistical Computing, Vienna, Austria; <https://www.R-project.org/>).

## RESULTS

### Cohort Description

During the study period, out of 1275 blood culture–proven sepsis episodes, 383 occurred in 380 previously healthy children (Figure 1). *Streptococcus pneumoniae*, *S. aureus*, Group A and B streptococcus, *N. meningitidis*, and *H. influenzae* accounted for 271/383 (70%) sepsis episodes. There were 94 patients excluded, predominantly because of a lack of consent or lack of access to DNA. There was 1 case of *H. influenzae B* sepsis in an unvaccinated child that was excluded. The final WES cohort consisted of 176 children, including 8 (5%) with recurrent bacterial sepsis (Table 1). Of these, 38.64% of patients developed organ dysfunction and 37.5% required pediatric intensive care unit (PICU) admission for sepsis. Of the 176 children, 5 (2.8%) died.

### Identification of Putatively Causative Primary Immunodeficiency Variants

WES was successfully performed in all 176 study participants. In total, 8 463 144 variants were identified. After filtering based on the predicted function impact, predicted pathogenicity, and MAF, 35 966 variants were retained (Supplementary Figure 1). We then restricted analyses to rare variants in 240 PID genes known to be associated with bacterial infection: 41 unique rare and predicted pathogenic VUS were identified in 35 out of 176 participants (20%) across 24 PID genes (Table 2; Supplementary Figure 2). Biallelic (homozygous) variants were found in 1 participant in 1 gene, X-linked variants were found in 5 participants in 5 genes, and monoallelic variants were found in 35 study participants in 18 genes. In 30/35 patients (86%), only 1 variant was found, whereas in 5/35 (14%) patients, 2 or 3 variants were discovered. Out of the 41 variants, 3 exact variants in 3/176 participants (2%) were identical to previously reported variants from patients with a PID phenotype with a bacterial infection (Table 3).

### Characterization and Distribution of Primary Immunodeficiency Gene Variants in Children with Sepsis

The identified variants were distributed across all PID groups (Table 2; Supplementary Figures 2 and 3; Supplementary Table 4) [20]. They were most commonly found in *CHD7* ( $n = 6$  patients) and *SAMD9*, *TCF3*, and *BACH3* ( $n = 3$  each). The 3 previously reported PID variants related to combined immunodeficiencies with associated symptoms, phagocyte defects, and complement defects (Table 3).


We did not observe any association of variants with specific pathogens or a focus of infection (Table 1;  $P > .10$ ). They were found in 13 out of 54 patients with a *S. pneumoniae* infection

(24%), in 7 out of 44 patients with a *S. aureus* infection (16%), in 6 out of 33 patients with a Group A streptococcal infection (18%), in 4 out of 17 patients with a Group B streptococcal infection (24%), in 2 out of 16 patients with an *N. meningitidis* infection (13%), and in 3 out of 12 patients with an *H. influenzae* infection (25%; Table 1; Supplementary Figure 3). There was no significant difference in the proportion of children found to carry PID variants between children  $<2$  years (12/56, 21%) and  $>2$  years of age (23/120; 19%;  $P = .8$ ; Figure 2; Supplementary Figure 4). No significant differences were observed when comparing the proportion of children with and without different PID variants in relation to the presence of organ dysfunction, PICU admission, the frequency of leukopenia, or the maximum C-reactive protein level measured during sepsis (Table 1). Variants were found in 4/8 (50%) patients with recurrent sepsis, versus 31/168 (18%) in children without recurrent sepsis ( $P = .051$ , Fisher test).

## DISCUSSION

In this prospective, population-based cohort of previously healthy children presenting with blood culture–proven bacterial sepsis, rare variants in genes previously reported to lead to PID associated with bacterial infections were substantially more common than previously assumed. It is important to note that the variants identified in our study are predicted but not functionally confirmed to affect gene functions and lead to immunodeficiency. Therefore, they must be considered VUS. Importantly, around 1 out of 50 (3/176; 2%) children with community-acquired sepsis that underwent WES carried exact variants that have been previously shown to result in PID associated with bacterial infections, which is higher than the estimated prevalence of PID in the population [22]. The variants identified in PID genes were distributed across all main IUIS categories [20]. We did not observe specific patterns in terms of pathogens, severity, inflammatory markers, or age at presentation that were associated with the likelihood of detecting such variants. These VUS in genes previously linked to susceptibility to bacterial infections within the context of clearly defined PID were found in otherwise apparently healthy children with bacterial sepsis. This finding may be explained either by a lack of functional relevance or by pleiotropy. WES represents a promising first step to investigate children with sepsis for potentially underlying PID. Future studies should combine WES with in-depth functional assays.

Understanding why a minority of children become very ill in the course of an infection remains among the mysteries of sepsis and may harbor clues for future targeted interventions [23]. Casanova et al [8] previously stated the hypothesis that life-threatening infections of childhood may represent the first manifestation of PID. The identification of PID in children with sepsis due to community-acquired bacteria has been reported



**Figure 1.** Enrollment flow diagram of WES cohort. Patients undergoing WES were previously healthy children with blood culture–proven sepsis caused by *S. pneumoniae*, *S. aureus*, Group A streptococcus, GBS, *N. meningitidis*, and *H. influenzae*. Abbreviations: CVC, central venous line; d, days; *E. cloacae*, *Enterobacter cloacae*; *E. coli*, *Escherichia coli*; *E. faecium*, *Enterococcus faecium*; GA, gestational age; GBS, Group B streptococcus; *H. influenzae*, *Haemophilus influenzae*; *N. meningitidis*, *Neisseria meningitidis*; *P. aeruginosa*, *Pseudomonas aeruginosa*; PCR, polymerase chain reaction; *S. aureus*, *Staphylococcus aureus*; *S. pneumoniae*, *Streptococcus pneumoniae*; SPSS, Swiss Pediatric Sepsis Study; w, weeks; WES, whole-exome sequencing.

in highly selected cases caused by *Pseudomonas aeruginosa* [9, 24, 25] or *S. pneumoniae*. A French study that investigated 163 children with pneumococcal disease using conventional immunologic screening reported underlying PID in 10% of cases [26], with a higher proportion of PID found in children >2 years

of age. Monogenic diseases resulting in PID have been shown to be associated with selected invasive bacterial infections, including Group B streptococcal and staphylococcal infections [27]. Several nonconventional PID, such as *IRAK-4*, *MyD88*, and *TIRAP* deficiencies [28–30], are characterized by incomplete



**Table 1. Demographic and Clinical Characteristics**

	All Children, n = 176, 100%	Children Without PID Variants, n = 141, 80%	Children with PID Variants of Uncertain Significance, n = 35, 20%	Children with Previously Reported PID Variant, n = 3, 2%
<b>Demographics</b>				
Age at sepsis onset, months	51.9 (15.3–126.5)	54.5 (15.4–127.2)	40.2 (9.1–111.7)	128.3 (27.5–170.4)
<b>Age group</b>				
28–365 days	41 (23%)	32 (23%)	9 (26%)	1 (33%)
1–4 years	53 (30%)	42 (30%)	11 (31%)	...
5–9 years	35 (20%)	28 (20%)	7 (20%)	...
10–16 years	47 (27%)	39 (28%)	8 (23%)	2 (67%)
Male	112 (64%)	87 (62%)	25 (71%)	2 (67%)
<b>Ethnicity<sup>a</sup></b>				
Caucasian	159 (90%)	127 (90%)	32 (91%)	3 (100%)
Asian	4 (2%)	3 (2%)	1 (3%)	...
African	4 (2%)	4 (3%)	...	...
other	3 (2%)	3 (2%)	...	...
<b>Site of infection</b>				
Primary bloodstream infection	22 (12%)	19 (13%)	3 (9%)	...
Pneumonia	47 (27%)	39 (28%)	8 (23%)	1 (33%)
Bone and joint infection	37 (21%)	30 (21%)	7 (20%)	1 (33%)
Central nervous system infection	33 (19%)	23 (16%)	10 (29%)	1 (33%)
Skin and soft tissue infection	15 (9%)	12 (9%)	3 (9%)	...
Ear, nose, and throat infection	9 (5%)	6 (4%)	3 (9%)	...
Toxic shock syndrome	4 (2%)	4 (3%)	...	...
Gastrointestinal system infection	2 (1%)	2 (1%)	...	...
Urinary tract infection	1 (1%)	1 (1%)	...	...
Other specific infection type	6 (3%)	5 (4%)	1 (3%)	...
<b>Pathogens</b>				
Gram-positive bacteria	148 (84%)	118 (84%)	30 (86%)	3 (100%)
<i>Streptococcus pneumoniae</i>	54 (31%)	41 (29%)	13 (37%)	2 (67%)
<i>Staphylococcus aureus</i>	44 (25%)	37 (26%)	7 (20%)	1 (33%)
Group A streptococci	33 (19%)	27 (19%)	6 (17%)	...
Group B streptococci	17 (10%)	13 (9%)	4 (11%)	...
Gram-negative bacteria	28 (16%)	23 (16%)	5 (14%)	...
<i>Neisseria meningitidis</i>	16 (9%)	14 (10%)	2 (6%)	...
<i>Haemophilus influenzae</i>	12 (7%)	9 (6%)	3 (9%)	...
<b>Severity of sepsis</b>				
<b>Organ dysfunction</b>				
No organ dysfunction present	108 (61%)	89 (63%)	19 (54%)	1 (33%)
≥1 organ dysfunction	68 (39%)	52 (37%)	16 (46%)	2 (67%)
C-reactive protein, mg/L <sup>b</sup>	192 (94–260)	186 (95–266)	198 (88–237)	192 (165–200)
Leukopenia present <sup>c</sup>	30 (17%)	21 (15%)	9 (26%)	1 (33%)
PICU/NICU admission	66 (38%)	53 (38%)	13 (37%)	2 (67%)
Length of PICU stay, days	5 (2–9)	4 (2–9)	7 (2–12)	19 (2–36)
Length of hospital stay after sepsis onset, days	10 (7–15)	10 (7–15)	11 (7–15)	10 (6–55)
Invasive ventilation	36 (20%)	29 (21%)	7 (20%)	1 (33%)
Inotrope requirement	39 (22%)	31 (22%)	8 (23%)	2 (67%)
Case fatality	6 (3%)	5 (4%)	1 (3%)	...

Data are from children with blood culture–proven bacterial sepsis in relation to whole-exome sequencing findings of putatively pathogenic variants in known PID genes. Characteristics of children without a PID variant (n = 141) are compared to children in whom a PID variant of uncertain significance was found (n = 35, including novel and previously reported PID variants) and children in whom a previously reported PID variant was found (n = 3). Categorical variables are given as frequencies and percentages and continuous variables as median and interquartile range. Column percentages are given. Percentages are based upon available data for each variable.

Abbreviations: NICU, neonatal intensive care unit; PICU, pediatric intensive care unit; PID, primary immunodeficiency.

<sup>a</sup>Data not available in 6 episodes.

<sup>b</sup>Data not available in 9 episodes.

<sup>c</sup>Data not available in 3 episodes.

**Table 2. Clinical Characteristics**

Gene	Inheritance				Unique Variants	Unique Patients	Age in Months, Mean (Range)	Sex		Clinical Focus						Organ Dysfunction		Primary Pathogen Cultured						
	XL	AR	AD	...				M	F	CNS	ENT	Pneumonia	Bone/Joint	Cellulitis	Other	No Focus	0	≥1	HI	NM	GBS	GAS	SA	SP
	...	...	...	...				...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...
CID/CID+	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...		
BCL11B	...	...	2	2	2	84 (75–93)	2	...	1	1	...	...	...	...	1	1	...	...	...	1	...	1		
CHD7	...	...	6	6	6	61 (2–148)	5	1	3	...	2	...	...	...	2	4	...	...	1	1	1	2		
KDM6A	1	...	...	1	1	31 (31–31)	1	...	...	1	...	...	...	...	1	...	...	...	...	...	...	...		
KMT2D	...	...	2	2	2	100 (34–167)	...	2	...	1	...	1	...	...	1	1	...	...	...	1	1	...		
SAMD9	...	...	3	3	3	16 (1–40)	2	1	2	...	...	1	...	...	1	2	...	...	1	1	1	...		
SEMA3E	...	...	1	1	1	14 (14–14)	1	...	1	...	...	...	...	...	...	1	1	...	...	...	...	...		
STAT3	...	...	1	1	1	34 (34–34)	...	1	...	1	...	...	...	...	1	...	...	...	...	...	...	1		
TBX1	...	...	1	1	1	6 (6–6)	1	...	1	...	...	...	...	...	1	...	...	...	...	...	...	1		
WAS	1	...	...	1	1	7 (7–7)	1	...	1	...	...	...	...	...	...	1	...	...	...	...	...	1		
PAD/PIRD	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...		
IRF2BP2	...	...	1	1	1	148 (148–148)	1	...	...	...	1	...	...	...	1	...	...	...	...	...	...	1		
NFKB2	...	...	2	2	2	88 (43–132)	2	...	...	...	2	...	...	...	2	...	...	...	...	...	...	1		
PTEN	...	...	1	1	1	132 (132–132)	...	1	1	...	...	...	...	...	...	1	...	...	...	...	...	1		
TCF3	...	...	3	3	3	63 (2–100)	3	...	1	...	...	1	...	1	3	...	...	...	1	1	1	...		
TNFRSF13B	...	...	1	1	1	64 (64–64)	1	...	...	1	...	...	...	...	1	...	...	...	...	...	...	1		
BACH2	...	...	3	3	3	109 (23–176)	3	...	...	1	2	...	...	...	2	1	...	1	...	...	...	2		
NFAT5	...	...	1	1	1	5 (5–5)	...	1	1	...	...	...	...	...	...	1	...	...	...	...	...	1		
PD/IIID	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...		
CYBB	1	...	...	1	1	128 (128–128)	1	...	...	...	1	...	...	...	1	...	...	...	...	...	...	1		
CXCR4	...	...	2	2	2	41 (34–48)	...	2	...	1	1	...	...	...	...	2	...	...	...	2	...	...		
IL17F	...	...	1	1	1	112 (112–112)	...	1	...	...	...	1	...	...	1	...	...	...	...	1	...	...		
IRAK1	1	...	...	1	1	4 (4–4)	1	...	...	...	...	...	...	1	1	...	...	...	...	...	...	1		
AID/CD	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...	...		
PLCG2	...	...	2	2	2	109 (75–143)	1	1	...	2	...	...	...	...	1	1	...	...	...	...	...	2		
POLA1	1	...	...	1	1	109 (109–109)	1	...	...	...	1	...	...	...	1	...	...	...	...	...	...	1		
C4A	...	...	1	1	1	5 (5–5)	1	...	...	...	...	...	...	1	1	...	...	...	...	1	...	...		
CFH	...	...	2	2	2	108 (38–179)	1	1	...	1	...	...	...	...	...	2	1	...	...	...	...	1		

Data are from children with blood culture-proven bacterial sepsis where a variant of unknown significance in a PID gene was found (n = 35) are shown for each PID according to the International Union of Immunological Societies classification. All genes are named according to the sequence variant nomenclature as defined by the Human Genome Variation Society (HGVS).

Abbreviations: AD, autosomal-dominant; AID, autoinflammatory disorders; AR, autosomal-recessive; CD, complement defects; CID, combined immunodeficiencies; CID+, CID with associated symptoms; CNS, central nervous system infection; ENT, ear, nose, and throat infection; F, female; GAS, Group A streptococcus; GBS, Group B streptococcus; HI, *Haemophilus influenzae*; IID, innate immune defects; M, male; NM, *Neisseria meningitidis*; PAD, predominantly antibody disorders; PD, phagocyte defects; PID, primary immunodeficiency; PIRD, primary immune dysregulatory disorders; SA, *Staphylococcus aureus*; SP, *Streptococcus pneumoniae*; XL, X-linked.

**Table 3. Rare Variants Previously Reported in Patients with Primary Immunodeficiency and Bacterial Infections**

IUIS Category	Sex	Age, Days	Pathogen	Clinical Focus	Gene	HGVS (protein)	Inheritance	Read Depth	Frequencies in GnomAD	PubMed ID
CID+	M	223	SP	CNS	WAS	E131K (p.Glu131Lys)	XL	25	0,00260066	Missense variant (15284122)
PD	M	3905	SA	Bone/joint	CYBB	G364R (p.Gly364Arg)	XL	40	0,00394664	Missense variant (10089913)
CD	F	5443	SP	Pneumonia	CFH	P503A (p.Pro503Ala)	AD	176	1,63E-05	Missense variant (24906858)


Data are for variants found in children with blood culture–proven sepsis. Host and pathogen characteristics are shown of the sepsis episodes (n = 3) where a patient was found to carry a previously reported PID variant associated with bacterial infection, as are details of the identified variants.

Abbreviations: AD, autosomal-dominant; CD, complement defects; CID+, combined immunodeficiencies with associated symptoms; CNS, central nervous system infection; F, female; gnomAD, Genome Aggregation Database; HGVS, Human Genome Variation Society; IUIS, International Union of Immunological Societies; M, male; PD, phagocyte defects; PID, primary immunodeficiency; SA, *Staphylococcus aureus*; SP, *Streptococcus pneumoniae*; XL, X-linked.

penetrance and variable pathogen specificity. The effects of some PID on increased susceptibility to infection may decrease with age if patients survive infections during childhood [28]. In our study, we did not find any association between the presence of PID VUS and increased disease severity, measured by a need for PICU admission, the number of organ dysfunctions, or septic shock [31]. Blood culture–proven sepsis represents an extreme phenotype from an evolutionary perspective, given the high fatality rate of bacteremia in the absence of antimicrobial therapy. In contrast, extreme phenotypes, as defined by contemporary

medicine where intensive care support is available, are subject to different host genetics, pathogens, and environmental factors. Importantly, the time to antibiotics represents a major determinant of severity [4, 32], and the specific setting in Switzerland has to be considered, including a low proportion of socioeconomically disadvantaged children and a high-density pediatric hospital network, potentially resulting in earlier treatment.

Children requiring life support due to severe infections in PICUs are currently not routinely investigated for the presence of PIDs. No specific guidelines exist for clinicians when facing



**Figure 2.** Number of previously healthy children with blood-culture-proven sepsis in relation to age and severity at presentation. Children testing positive for a rare VUS associated with primary immunodeficiency are shown in blue; in comparison, children where no VUS associated with primary immunodeficiency was found are shown in light gray. Abbreviations: GAS, group A streptococcus; GBS, Group B streptococcus; HI, *Haemophilus influenzae*; NM, *Neisseria meningitidis*; SA, *Staphylococcus aureus*; SP, *Streptococcus pneumoniae*; VUS, variant of uncertain significance; y, years.

the question of whether a child with sepsis may harbor a PID [10]. There is a need for studies defining indications for PID investigations in children with sepsis, coupled with increased education and awareness of pediatric intensivists, infectious disease specialists, and pediatricians on the topic. Selection rules based on pathogens, severity, or a history of familial reoccurrence alone could be inaccurate, as demonstrated by the absence of clear patterns in our study. In addition, commonly used immunological investigations, such as the measurement of total and specific immunoglobulin, complement protein concentrations, and basic lymphocyte populations, will miss a substantial proportion of PID in comparison to WES. Importantly, recognizing and accurately diagnosing underlying PID in children presenting with sepsis is important given the risk of recurrence of infection, with potentially fatal but preventable outcomes [9]. The challenges in interpreting the findings of our study highlight that while next-generation sequencing (NGS) represents a promising diagnostic tool in children with sepsis, NGS-based genetic testing must be followed by specifically indicated functional tests if WES is to be considered as a routine diagnostic approach. Validation of the findings will require immunological follow-up of the study cohort, including assessments of subsequent invasive infections. Unfortunately, the study approval was restricted to singleton testing. Future studies embarking on unravelling the genetic contribution to childhood sepsis need to incorporate functional analyses both during disease and (if the patient survives) during recovery, including extended investigations of parents and siblings, as indicated. In view of our findings of a high number of VUS across all IUIS categories, the availability of immune-phenotyping platforms to assess a broad range of immunological pathways carries strong promise [33].

NGS has been successfully applied both to discover novel disease-causing gene variants and to obtain a molecular diagnosis of monogenic conditions [34, 35], and may be cost effective in comparison to standard genetic diagnostic procedures [35]. Yet, as a result of the increasing number of patients undergoing WES [11, 36], the field of clinical immunology is rapidly evolving, and expanding cohorts demonstrate considerable variability of the phenotypes. The mechanisms underlying incomplete penetrance and variable expressivity remain mostly unexplained and are likely complex, as demonstrated by the recent discovery of the role of anti-lipoteichoic acid (LTA) antibody deficiencies in patients with a *TIRAP* deficiency [27]. We applied stringent filtering criteria including several control cohorts, and restricted analyses to rare variants predicted to have functional impacts in genes known to lead to PID phenotypes associated with bacterial infection. Despite this approach, confirming that rare VUS identified by WES are pathogenic remains a challenge [12, 37]. Rare variants in genes previously demonstrated to result in Mendelian disease may also contribute to the risks of infection through complex and polygenic mechanisms [38]. A recent landmark study using electronic

health record-based phenotype risk scores in large, genotyped cohorts identified a substantial number of undiagnosed patients harboring rare variants and phenotypes related to unrecognized Mendelian diseases [39]. A combination of international cohorts will be required to provide the power for the statistical validation of enriched variants or pathways, or to test the hypothesis that complex/polygenic predispositions could also play a role in human susceptibility to sepsis.

Despite these challenges, our findings are based on a high-quality, prospective, population-based study restricted to the gold standard of invasive infection (bacteraemia). The design of this national cohort minimized an inclusion bias in comparison to the majority of immunologic studies, commonly based on highly selected referral patients with severe or recurrent disease. We carefully excluded children with underlying comorbidities, in order to focus on community-acquired sepsis in children that were apparently healthy before hospital admission. We acknowledge that this may have led to the exclusion of children harboring PID associated with a congenital disease or syndromes. We restricted WES to the most common pathogens causing community-acquired sepsis [14], and acknowledge that PIDs potentially may be more common in children presenting with unusual bacterial pathogens.

Our study has several additional limitations. Most importantly, we did not functionally verify the pathogenicity of the variants identified in PID genes. While we used stringent filtering and pathogenicity prediction criteria aligned with best practices, and assessed whether variants had been previously demonstrated to lead to PID with bacterial infection, their pathogenicity has not been demonstrated, thus resulting in a possible overestimation of the proportion of PID-related sepsis. Functional validation in our and other independent cohorts will be required to define the true proportion of PID causing sepsis in children. Second, we only focused on those PID genes previously demonstrated to be associated with bacterial infection, which may have led to the exclusion of causative variants, thereby resulting in an underestimation of the proportion of PID-related sepsis. In addition, the genetic backgrounds for several PID, mainly disorders affecting antibody production, are unknown, which may again result in an underestimation of PID. Considering the rapid expansion of recently identified novel PID, it is thus also likely that a subset of patients may harbor disease-conferring yet unidentified novel PID. Experimental validation to define the causal relationship between genotype and phenotype is crucial during the investigation of novel PID candidates. Third, an intrinsic limitation in WES is the inability to detect deep intronic and intergenic genetic variants. Finally, we did not assess the microbiological factors determining pathogen virulence, such as toxins.

In conclusion, applying WES to a population-based cohort of previously healthy children presenting with bacterial sepsis allowed for the detection of VUS in previously reported PID genes in a substantial proportion of sepsis cases. Our study



explores the possible contribution of host genetic variations to sepsis susceptibility. Future studies combining NGS with functional testing are required to validate whether unrecognized PIDs contribute significantly to sepsis at the populational level. Our findings indicate an urgent need for evidence-based recommendations on the optimal selection of children with sepsis for genetic and functional investigations to identify PIDs.

### Supplementary Data

Supplementary materials are available at *Clinical Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

### Notes

**Author contributions.** L. J. S. designed and supervised the study, oversaw analyses, wrote the first draft, had full access to all the data in the study, and takes responsibility for the integrity of the data and the accuracy of the data analysis. A. B., S. A., and J. F. contributed to the study design, performed analyses of bioinformatics data, revised the manuscript, and approved the final version. J. T. performed analyses, contributed to the first draft, and approved the final version. C. B., C. A., P. K. A. A., K. M. P.-B., E. G., M. S., U. H., S. B.-S., C. R., T. R., A. N.-L., and C. R. K. were involved in the study design, patient recruitment, data analysis, and manuscript preparation, and approved the final version. V. S.-S. and E. B. performed analyses of bioinformatics data in meningococcal patients. V. S.-S., E. B., F. M.-T., V. W., J. H., L. C., and M. L. contributed to the study design and manuscript revision, and approved the final version. For the full list of investigators in the European Childhood Life-threatening Infectious Disease Study (EUCLIDS) consortium and the Swiss Pediatric Sepsis Study, see the Supplementary Material.

**Acknowledgements.** The authors thank the participating patients and their families. They also thank the study nurses at each study site and John D Wilson and Yann Dubois (Global Health Institute, School of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland).

**Disclaimer.** The funding agencies had no role in the study design, data collection, data analysis, data interpretation, or writing of the report.

**Financial support.** This work was supported by the Swiss National Science Foundation (grant number 342730\_153158/1), the Swiss Society of Intensive Care, the Bangerter Foundation, the Vinetum and Borer Foundation, and the Foundation for the Health of Children and Adolescents. The EUCLIDS consortium has received funding from the European Union's Seventh Framework program (grant number EC-GA 279185). L. J. S. is supported by a Practitioner Fellowship of the National Health and Medical Research Council of Australia and New Zealand, and by the Children's Hospital Foundation, Brisbane, Australia.

**Potential conflicts of interest.** U. H. has received personal fees from Sanofi Pasteur USA and Sanofi France for the Global Pertussis Initiative and Collaboration of European Experts on Pertussis Awareness Generation (CEEPAG), outside the submitted work. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

### References

- Fleischmann C, Scherag A, Adhikari NK, et al; International Forum of Acute Care Trialists. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. *Am J Respir Crit Care Med* **2016**; *193*:259–72.
- Schlapbach LJ, Straney L, Alexander J, et al; Australian and New Zealand Intensive Care Society (ANZICS) Paediatric Study Group. Mortality related to invasive infections, sepsis, and septic shock in critically ill children in Australia and New Zealand, 2002–13: a multicentre retrospective cohort study. *Lancet Infect Dis* **2015**; *15*:46–54.
- Fleischmann-Struzek C, Goldfarb DM, Schlattmann P, Schlapbach LJ, Reinhart K, Kissoon N. The global burden of paediatric and neonatal sepsis: a systematic review. *Lancet Respir Med* **2018**; *6*:223–30.
- Launay E, Gras-Le Guen C, Martinot A, et al. Why children with severe bacterial infection die: a population-based study of determinants and consequences of sub-optimal care with a special emphasis on methodological issues. *PLOS One* **2014**; *9*:e107286.
- Schlapbach LJ, MacLaren G, Festa M, et al; Australian and New Zealand Intensive Care Society (ANZICS) Centre for Outcomes & Resource Evaluation (CORE) and ANZICS Paediatric Study Group. Prediction of pediatric sepsis mortality within 1 h of intensive care admission. *Intensive Care Med* **2017**; *43*:1085–96.
- Obel N, Christensen K, Petersen I, Sørensen TI, Skytthe A. Genetic and environmental influences on risk of death due to infections assessed in Danish twins, 1943–2001. *Am J Epidemiol* **2010**; *171*:1007–13.
- Alcais A, Quintana-Murci L, Thaler DS, Schurr E, Abel L, Casanova JL. Life-threatening infectious diseases of childhood: single-gene inborn errors of immunity? *Ann N Y Acad Sci* **2010**; *1214*:18–33.
- Casanova JL, Abel L. Primary immunodeficiencies: a field in its infancy. *Science* **2007**; *317*:617–9.
- Asgari S, McLaren PJ, Peake J, et al; Swiss Pediatric Sepsis Study. Exome sequencing reveals primary immunodeficiencies in children with community-acquired *Pseudomonas aeruginosa* sepsis. *Front Immunol* **2016**; *7*:357.
- Randolph AG, McCulloh RJ. Pediatric sepsis: important considerations for diagnosing and managing severe infections in infants, children, and adolescents. *Virulence* **2014**; *5*:179–89.
- Maffucci P, Filion CA, Boisson B, et al. Genetic diagnosis using whole exome sequencing in common variable immunodeficiency. *Front Immunol* **2016**; *7*:220.
- Biesecker LG, Nussbaum RL, Rehm HL. Distinguishing variant pathogenicity from genetic diagnosis: how to know whether a variant causes a condition. *JAMA* **2018**; *320*:1929–30.
- Giannoni E, Berger C, Stocker M, et al; Swiss Pediatric Sepsis Study Group. Incidence and outcome of Group B streptococcal sepsis in infants in Switzerland. *Pediatr Infect Dis J* **2016**; *35*:222–4.
- Agyeman PKA, Schlapbach LJ, Giannoni E, et al; Swiss Pediatric Sepsis Study. Epidemiology of blood culture-proven bacterial sepsis in children in Switzerland: a population-based cohort study. *Lancet Child Adolesc Health* **2017**; *1*:124–33.
- Goldstein B, Giroir B, Randolph A; International Consensus Conference on Pediatric Sepsis. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. *Pediatr Crit Care Med* **2005**; *6*:2–8.
- Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. *Bioinformatics* **2010**; *26*:589–95.
- Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* **2009**; *25*:1754–60.
- McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res* **2010**; *20*:1297–303.
- Van der Auwera GA, Carneiro MO, Hartl C, et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. *Curr Protoc Bioinformatics* **2013**; *43*:11.10.1–11.10.33.
- Tangye SG, Al-Herz W, Bousfiha A, et al. Human Inborn Errors of Immunity: 2019 Update on the Classification from the International Union of Immunological Societies Expert Committee. *J Clin Immunol* **2020**; *40*:24–64. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/31953710>
- Rentsch P, Witten D, Cooper GM, Shendure J, Kircher M. CADD: predicting the deleteriousness of variants throughout the human genome. *Nucleic Acids Res* **2019**; *47*:D886–94.
- Bousfiha AA, Jeddane L, Ailal F, et al. Primary immunodeficiency diseases worldwide: more common than generally thought. *J Clin Immunol* **2013**; *33*:1–7.
- Schlapbach LJ. Paediatric sepsis. *Curr Opin Infect Dis* **2019**; *32*:497–504.
- Stergiopoulou T, Walsh TJ, Seghaye MC, et al. Deficiency of interleukin-1 receptor-associated kinase 4 presenting as fatal *Pseudomonas aeruginosa* bacteremia in two siblings. *Pediatr Infect Dis J* **2015**; *34*:299–300.
- Record J, Malinova D, Zenner HL, et al. Immunodeficiency and severe susceptibility to bacterial infection associated with a loss-of-function homozygous mutation of MKL1. *Blood* **2015**; *126*:1527–35.
- Gaschignard J, Levy C, Chrabieh M, et al. Invasive pneumococcal disease in children can reveal a primary immunodeficiency. *Clin Infect Dis* **2014**; *59*:244–51.
- Israel L, Wang Y, Bulek K, et al. Human adaptive immunity rescues an inborn error of innate immunity. *Cell* **2017**; *168*:789–800.e10.
- Picard C, von Bernuth H, Ghandil P, et al. Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency. *Medicine (Baltimore)* **2010**; *89*:403–25.
- Picard C, Puel A, Bonnet M, et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. *Science* **2003**; *299*:2076–9.
- Della Mina E, Borghesi A, Zhou H, et al. Inherited human IRAK-1 deficiency selectively impairs TLR signaling in fibroblasts. *Proc Natl Acad Sci USA* **2017**; *114*:E514–23.

31. Schlapbach LJ, Kissoon N. Defining pediatric sepsis. *JAMA Pediatr* **2018**; 172:312–4.
32. Weiss SL, Fitzgerald JC, Balamuth F, et al. Delayed antimicrobial therapy increases mortality and organ dysfunction duration in pediatric sepsis. *Crit Care Med* **2014**; 42:2409–17.
33. Carr EJ, Dooley J, Garcia-Perez JE, et al. The cellular composition of the human immune system is shaped by age and cohabitation. *Nat Immunol* **2016**; 17:461–8.
34. Meng L, Pammi M, Saronwala A, et al. Use of exome sequencing for infants in intensive care units: ascertainment of severe single-gene disorders and effect on medical management. *JAMA Pediatr* **2017**; 171:e173438.
35. Tan TY, Dillon OJ, Stark Z, et al. Diagnostic impact and cost-effectiveness of whole-exome sequencing for ambulant children with suspected monogenic conditions. *JAMA Pediatr* **2017**; 171:855–62.
36. Gallo V, Dotta L, Giardino G, et al. Diagnostics of primary immunodeficiencies through next-generation sequencing. *Front Immunol* **2016**; 7:466.
37. MacArthur DG, Manolio TA, Dimmock DP, et al. Guidelines for investigating causality of sequence variants in human disease. *Nature* **2014**; 508:469–76.
38. Lupski JR, Belmont JW, Boerwinkle E, Gibbs RA. Clan genomics and the complex architecture of human disease. *Cell* **2011**; 147:32–43.
39. Bastarache L, Hughey JJ, Hebring S, et al. Phenotype risk scores identify patients with unrecognized Mendelian disease patterns. *Science* **2018**; 359:1233–9.